Non-traumatic necrosis of bone (osteonecrosis) is associated with endothelial cell activation but not thrombophilia

Rheumatology

Volumn 47, Issue 8, 2008, Pages 1151-1155

  Séguin, Chantal ^a,b   Kassis, J ^b   Busque, L ^b   Bestawros, A ^b   Theodoropoulos, J ^b   Alonso, M L ^b   Harvey, E J ^b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Avascular necrosis; Endothelial cell activation; Inflammation; Osteonecrosis; Thrombophilia

Indexed keywords

CELL MARKER;

ADULT; ARTICLE; BIOCHEMISTRY; BLOOD CLOTTING; CELL ACTIVATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; FEMALE; FEMUR HEAD NECROSIS; FISHER EXACT TEST; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; INFLAMMATION; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOPHILIA;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FEMUR HEAD NECROSIS; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBOPHILIA;

EID: 47849100998     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken206     Document Type: Article

References (40)

1. Urbaniak JR, Jones JP Jr. In: Urbaniak JR, Jones JP, eds. Osteonecrosis: etiology, diagnosis, and treatment. IL: The American Orthopaedic Association, 1997;43-453.
2. Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: A common serious complication of allogenic bone marrow transplantation. Am J Med 1990;89:733-8.
3. Calza L, Manfredi R, Chiodo F. Osteonecrosis in HIV-infected patients and its correlation with highly active antiretroviral therapy (HAART). Presse Med 2003; 5:595-8.
4. Boland MJ, Hood G, Bastin ST, King AR, Grey A. Bilateral femoral head osteonecrosis after septic shock and multiorgan failure. J Bone Miner Res 2004;19:517-20.
5. Urbaniak JR, Harvey EJ. Revascularization of the femoral head in osteonecrosis. J Am Acad Orthop Surg 1998;6:44-54.
6. Veldhuizen PJV, Neff J, Murphey MD et al. Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol 1993;44:243-8.
7. Glueck CJ, Freiberg R, Glueck HI et al. Hypofibrinolysis: A common, major cause of osteonecrosis. Am J Hematol 1994;45:156-66.
8. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Sam Thromb Haemost 1990;16:207-16.
9. Gruppo R, Glueck CJ, McMahon RE et al. The pathophysiology of alveolar osteonecrosis of the jaw: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. J Lab Clin Med 1996;127:481-8.
10. Zalavras Ch, Dailiana Z, Elisaf M et al. Potential aetiological factors concerning the development of osteonecrosis of the femoral head. Eur J Clin Inv 2000;30:215-21.
11. Genez BM, Wilson MR, Houk RW et al. Early osteonecrosis of the femoral head: Detection in high-risk patients with MR imaging. Radiology 1988;168:521-4.
12. Marcus ND, Enneking WF, Massam RA. The silent hip in idiopathic aseptic necrosis. Treatment by bone-grafting. J Bone Joint Surg Am 1973;55:1351-66.
13. van der Meer FJM, Koster T, Vandenbroucke JP, Brief E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997;78:631-5.
14. Glueck CJ, Freiberg R, Tracy T, Stroop D, Wang P. Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. Clin Orthop 1997;334:43-66.
15. Korompilias AV, Gilkeson GS, Ortel TL, Seaber AV, Urbaniak JR. Anticardiolipin antibodies and osteonecrosis of the femoral head. Clin Orthop 1997;345:174-80.
16. Glueck CJ, Freiberg R, Glueck HI et al. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with stanozolol. Am J Hematol 1995;48:213-20.
17. Glueck CJ, Fontaine RN, Gruppo R et al. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop 1999;366:133-46.
18. Bjorkman A, Svensson PJ, Hillarp A, Burtscher IM, Runow A, Benoni G. Factor V Leiden and prothrombin gene mutation: Risk factors for osteonecrosis of the femoral head in adults. Clin Orthop 2004;425:168-72.
19. Zalavras C, Shah S, Birnbaum MJ, Frankel B. Role of apoptosis in glucocorticoid-induced osteoporosis and osteonecrosis. Crit Rev Eukaryot Gene Expr 2003; 13:221-35.
20. Starklint H, Lausten GS, Amoldi CC. Microvascular obstruction in avascular necrosis. Immunochemistry of 14 femoral heads. Acta Orthop Scand 1995;66:9-12.
21. Aaron RK, Ciombor DM. Coagulopathies and osteonecrosis. Curr Opin Orthop 2001;12:378-83.
22. Vila P, Hernandez MC, Lopez-Fernandez MF, Battle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994;72:209-13.
23. Wilson WA, Gharavi AE, Koike T. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
24. Miesbach W, Scharrer I, Asherson RA. High titers of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin's lymphoma. Clin Rheumatol 2007;26:95-7.
25. Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autaimmun 2000;15:163-72.
26. Zoghlami-Rintelen C, Vormittag R, Sailer T et al. The presence of IgG antibodies against beta2-glycoprotein 1 predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005;3:1160-5.
27. Vadasz Z, Misselevich I, Norman D, Peled E, Boss J.H. Localization of vascular endothelial growth factor during the early reparative phase of the rats' vessels deprivation-induced osteonecrosis of the femoral heads. Exp Mol Pathol 2004;77:145-8.
28. Kerachian MA, Harvey EJ, Cournoyer D, Chow TY, Séguin C. Avascular necrosis of the femoral head: vascular hypotheses. Endothelium 2006;13:237-44.
29. Rosenberg R, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. New Engl J Med 1999;340:1555-64.
30. Aird WC. Endothelial cell heterogeneity. Crit Care Med 2003;81(Suppl):S221-30.
31. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function and mechanisms. Circ Res 2007;100:158-73.
32. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007; 100:174-90.
33. Kerachian MA, Coumoyer D, Harvey EJ, Chow TY, Séguin C. Isolation and characterization of human bone-derived endothelial cells. Endothelium 2007; 14:115-21.
34. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischemic heart disease. Br J Haematol 1994;88:601-7.
35. Jager A, van Hinsbergh VW, Kostense PJ et al. von Willebrand Factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: The Hoorn study. Arterioscler Thromb Vasc Biol 1999; 19:3071-8.
36. Heijboer H, Brandjes DPM, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep venous thrombosis. New Engl J Med 1990;323:1512-6.
37. Koster T, Rosendaal FR, Briët E et al. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia. study). Blood 1995;85:2756-61.
38. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2132 consecutive unselected patients with venous throboembolism - results of the Spanish multicentric study on thrombophilia (EMET Study). Thromb Haemost 1997;77:444-51.
39. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZ J Med 1990;20:231-6.
40. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90:1-11.